Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Theranostics the key to UK drugs access?

This article was originally published in Clinica

Executive Summary

The growing healthcare potential of theranostics has been thrust into a UK debate on access to new drugs through the NHS. After the National Institute for Health and Clinical Excellence (NICE) rejected four products for the management of advanced renal cancer on the grounds of insufficient clinical and/or cost-effectiveness, oncology experts noted that better targeting of patients would make these drugs viable by improving response and effectiveness rates. In turn, this would reduce the waste of resources that results from ineffective treatment. In the case of the pharmaceutical products involved in the appraisal (Sutent, Avastin, Nexavar and Torisel), they reportedly exceeded NICE's usual cost-effectiveness threshold – £30,000 ($55,000) per quality-adjusted life year (QALY) – by a factor of six. Advanced renal cancer is diagnosed in around 3,600 people per year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041395

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel